Alaska Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• ADVANCE OUTCOMES: Ralinepag Reduces Clinical Worsening For PAH
  Ralinepag, a selective prostacyclin IP receptor agonist, significantly reduced the risk of first clinical worsening compared with placebo in patients with pulmonary arterial hypertension (PAH) but was associated with more adverse-event-related treatment discontinuations, according to results of the ADVANCE OUTCOMES trial published July 28 in The Lancet.
• PARTNER 3: 7-Year TAVR vs. SAVR Outcomes in Low-Risk Patients
  Both TAVR and SAVR were associated with a sustained, substantial improvement in patient-reported health status among patients with severe aortic stenosis (AS) considered at low risk, according to the seven-year outcomes of the PARTNER 3 trial published July 29 in JACC.
• JACC CKM Guideline Spotlight Issue Addresses Obesity, HF Prevention, More
  The recent release of the 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome marked an important step in defining evidence-based approaches to CKM prevention, risk assessment and treatment.
• Cardiogenic Shock and Mechanical Circulatory Support: Year in Review 2025
  The year 2025 was a landmark year for cardiogenic shock (CS) and mechanical circulatory support (MCS). Two major clinical guideline documents were published, the longest-duration follow-up data from the field's pivotal trial were released, and real-world registries continued to challenge trial generalizability.
• ACCEL Lite: Why Can’t We Prove Revascularization Is Better Than Medical Therapy for SIHD?
  In this interview, Allen J. Taylor MD, FACC and Sanjay Kaul, MBBS examine ‘Why Can’t We Prove Revascularization Is Better Than Medical Therapy for SIHD?’